Cell therapy for a rare disease- hairy cell leukemia variant Authors: Claire Fritz, Derek P Wong, Philip Rock, Richard Burack, Akshaya Radhakrishnan, Reshmi Parameswaran Published: 2024 ABSTRACT ABSTRACTHairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy. To address the shortcomings of current therapy for HCL-v, we investigated the activity of a BAFF ligand-based CAR-T cell which binds to all three BAFF receptors, BAFF-receptor, TACI, and BCMA. Here, we demonstrate that HCLv patient-derived cells highly express all three BAFF receptors and that BAFF CAR-T cells induce significant cytotoxicity in vitro against both cell lines and HCL-v patient cells. This cytotoxicity corresponds with significant CAR-T cell activation, degranulation, and release of pro-inflammatory cytokines after co-incubation with HCLv cells. Furthermore, we successfully generated BAFF CAR-T cells directly from an HCLv patient and observed direct autologous killing against patient tumor cells in vitro. These HCLv patient-derived CAR-T cells were also effective in killing the Hair-M cell line and tumor cells derived from a different HCLv patient. Lastly, we also developed two mouse xenograft models for HCL, a subcutaneous Bonna-12 model and intravenous Hair-M xenograft model. We observed decreases in tumor burden and prolonged overall survival without significant toxicity. In conclusion, here we show that BAFF CAR-T cells exert anti-tumor effects in vitro and in vivo against multiple cell lines and patient-derived HCL-v samples and may be a successful therapeutic strategy for HCLv patients. Introduction Hairy cell leukemia variant (HCL-v) is a provisional entity with intermediate features between classical HCL and B-cell prolymphocytic leukemia. HCL-v makes up approximately 0.4% of chronical lymphoid malignancies and represents 10% of total HCL cases.1,2 The median age of diagnosis of HCL-v is 71, and patients present with splenomegaly, leukocytosis without monocytopenia, and a hypercellular bone marrow that can be aspirated.3 Despite some overlapping clinical and morphological features, HCL-v is more clinically aggressive than classical HCL and responds poorly to purine analogs, which are very effective in reducing disease burden in classical HCL patients. Biologically, these cells lack expression of classical HCL markers including CD25, TRAP, and BrafV600E, the genetic event thought to drive classical HCL. As such, these patients do not benefit from BRAF targeting therapeutics. Due to the rarity of HCL-v and paucity of clinical trial data, an accepted treatment regimen has not yet been established for these patients. Splenectomy has been associated with improved clinical outcomes and symptom relief. Medically, monotherapy with PNAs is currently not recommended, but combination therapy with rituximab has been shown to be efficacious in limited clinical trial data.4 However, repeated treatment with purine analogs can cause profound myelosuppression and risk of infection with common or opportunistic organisms.5 Although interferon alpha (IFN-α) may induce rapid hematological responses in classical HCL patients, the response rate in HCL-v is poor, and this therapy is not recommended for these patients.6 Targeted inhibitors against the BCR signaling axis are a more promising approach. A phase 2 clinical trial found that ibrutinib, a Bruton’s tyrosine kinase inhibitor, was effective in lessening disease burden and may be useful for patients who do not respond to other therapies.7 Additionally, there is a phase 2 trial investigating the MEK inhibitor binimetinib in variant HCL patients.8 Up to half of HCL-v patients have activating mutations in MEK. The development and application of targeted, disease-specific therapeutics may lessen disease burden in a similar manner while also evading the toxicities associated with PNAs. Chimeric antigen receptor (CAR)-T cell immunotherapy has emerged in recent decades as a promising therapeutic option for many hematological malignancies.9–15 Since 2017, the FDA has approved 6 CAR T-cell therapies targeting CD19 or BCMA for the treatment of certain non-Hodgkin’s lymphomas, acute lymphoblastic leukemia, or multiple myeloma.16 Despite their clinical success, relapse of disease remains as a limitation of current approaches that target only one tumor-associated antigen due to loss of the CAR-specific antigen, or antigen escape.17–19 Furthermore, the development of CAR-T cell therapy for the treatment of variant HCL has received little attention relative to other B-cell cancers, with only one phase 1 clinical trial investigating anti-CD22 CAR-T cells currently underway [NCT04815356]. We recently developed a novel CAR T-cell product which targets the three receptors of B-cell activating factor (BAFF): BAFF-Receptor, BCMA, and TACI.20 BAFF is a soluble ligand that is critical for B-cell maturation and development, and aberrant upregulation of its receptors has been implicated in numerous B-cell neoplasms.21–24 Our CAR construct contains intracellular CD28 and OX40/CD134 costimulatory domains, the CD3ζ signaling domain, and CD28 transmembrane domain.20 A truncated BAFF sequence that encompasses most of the extracellular domain of the natural human BAFF ligand is included, allowing the CAR T-cells to effectively bind to the three receptors of BAFF.20 We hypothesize that targeting all three BAFF receptors decreases the risk of antigen escape and relapse, which is a major clinical shortcoming of current HCL treatment. Furthermore, by targeting BAFF receptors and, therefore, B-cell precursors, our CAR T-cells may be more selective to malignant B cells and decrease the risk of immunosuppression. Our BAFF CAR-T cells are effective in preclinical models of mantle cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia models, and are currently being investigated in a phase I clinical trial for relapsed or refractory non-hodgkin lymphoma.20 Here, we demonstrate that multiple HCL cell lines and primary spleen-derived patient samples overexpress BAFF-R, BCMA, and TACI. Co-culture of our CAR T-cells with HCL cell lines or patient samples results in significantly enhanced cytotoxicity of HCL-v cells relative to co-culture with control T-cells. Functional analysis of the CAR-T cells after co-culture reveals increased activation and degranulation, as measured by CD69 and CD107a expression. The CAR-T cells also released significant pro-inflammatory cytokines and cytotoxic enzymes upon co-culture. Additionally, we generated BAFF CAR-T cells directly from an HCL-v patient and demonstrate in vitro autologous cancer cell killing as well as efficient killing against cells derived from a different patient. These findings were translated into two novel in vivo models, a subcutaneous model with Bonna-12 cells and intravenous model with the Hair-M cell line. In both models, intratumoral or intravenous treatment with BAFF CAR-T cells significantly blunted tumor growth without observed toxicity. Our findings suggest that our CAR-T cells targeting BAFF-R, BCMA, and TACI may be a successful alternative therapeutic approach to treating HCL-v. Methods HCL cells receptor expression HCL cell lines (Bonna-12, Hair-M, Mo-B) and patient samples were washed with PBS and stained with a panel of FITC-conjugated CD19 (Biolegend, catalog # 392508, clone 4G7), PE-conjugated BCMA (Biolegend, catalog # 357504, clone 19F2), PE/CY7-conjugated TACI (Biolegend, catalog # 311908, clone 1A1), and APC-conjugated BAFF-R (Biolegend, catalog # 316916, clone 11c1) for 15 min at room temperature in the dark. After the incubation, 1 mL of PBS was added, and cells were centrifuged and reconstituted in 50 μL of PBS and run on flow cytometry. Live cells were gated on by FSC/SSC, and the level of expression of these receptors was compared by histogram overlay. The median fluorescent intensity (MFI) for each sample is also reported. An unstained control and antigen-negative cell control (primary natural killer cells, “NK”) were included for each cell line and patient sample for comparison. Additionally, the mantle cell lymphoma-line JeKo is included as a positive control for receptor expression. For the autologous experiments, the expression of the BAFF receptors was measured on the patient’s cancer cells by gating on CD19+ cells in the PBMC population. Receptor expression is compared to that of PBMCs from a healthy donor. HCL patient data All sample and data collection falls under the Hematological Malignancy Procurement Program of the Wilmot Cancer Institute at the University of Rochester Medical Center. Diagnostic data were abstracted from the clinical data system for anonymized use pertaining to sample specific data contained in the original pathology reports. All samples are obtained by the surgical pathology department from biopsies performed for diagnostic purposes. Tissue samples provided for tissue banking are deemed discarded and of no further clinical significance and hence obtained under an approved IRB-exemption protocol. IHC and flow cytometry antibodies were provided by Dako and Beckman-Coulter, respectively. T-cell isolation and CAR-T cell production Blood samples from healthy human donors were obtained from the Hematopoietic and Cellular Therapy Core at Case Western. Peripheral blood mononuclear cells were isolated by density gradient separation with Ficoll-Paque. CD3+ T-cells were purified using the MojoSort human CD3 T-cell isolation kit, following the manufacturer’s instructions (Biolegend, catalog #480021). T-cells were activated using the Dynabeads human T-Activator CD3/CD28 kit (Gibco, catalog# 11161D). T-cells were cultured in complete Advanced RPMI 1640 medium with 2 ng/ml of hIL-2 (PeproTech) and activation beads for 48 h. Hek293FT cells were used to produce lentivirus supernatants containing BAFF CAR. One milliliter of Opti-MEM medium containing 3750 ng of the psPax2 packaging plasmid, 1250ng of the pMD2G envelop plasmid, 5000 ng of the BAFF CAR vector, and 10 μL of X-tremeGENE HP transfection reagent (Sigma, catalog# 06 366 236 001) were added to each 10 cm plate of Hek293FT cells. Supernatant from these cells were collected at 48 and 72 h, and Lenti-X Concentrator (Clontech, catalog #PT4421-2) was added. After overnight incubation with Lenti-X Concentrator, the supernatant was centrifuged at 1500×g for 45 minutes at 4°C, and the virus was resuspended in complete RPMI. BAFF CAR virus with polybrene was added to activated T-cells, which were then spinoculated at 1000 × g for 90 min at 32°C. CAR T-cells were expanded with advanced RPMI in the presence of IL-2 (2 ng/ml), IL-7 (10 ng/ml), and IL-15 (5 ng/ml). This protocol was followed to generate BAFF CAR-T cells from the peripheral blood of an HCL-v patient. Cytotoxicity assay HCL cell lines or patient spleen cells were labeled with eFlour670 dye (Invitrogen, catalog # 65-0840-85). Control or BAFF CAR-T cells were co-incubated at various effector: target ratios (20:1, 10:1, 5:1, or 2.5:1) with the fluorescently labeled cancer cells in complete RPMI medium with 2 ng/ml of hIL-2. After 16–48 h of incubation, all cells were stained with propidium iodide (Cell Signaling Technology, catalog # 4087S). APC-positive labeled cancer cells were gated on via flow cytometry, and the percentage of PE- and APC-positive cancer cells was reported as dead cancer cells. Patient-derived CAR-T cells T-cells were processed from the peripheral blood of an HCLv patient as previously described. PBMCs that were not used for T-cell isolation were saved and used as the target cells in autologous cytotoxicity experiments. The total patient-derived PBMCs were co-incubated with the BAFF CAR-T cells generated from the same patient at a 10:1 or 20:1 ratio for 16–24 h. After the co-incubation, the cells were stained with APC-conjugated CD22 (Biolegend, catalog #302510) to gate on B-cells. Percentage of live target cells by FSC/SSC gating were compared and reported. The patient-derived BAFF CAR-T cells were also co-incubated with fluorescently labeled Hair-M cells or cancer cells from another HCLv patient (PT 6) for 24 h. APC positive cells were gated, and percentage of live cells is reported by FSC/SSC gating. CD69 activation assay Control T-cells or BAFF CAR T-cells were co-incubated with HCL cell lines or patient samples at a 5:1 effector: target ratio for 16 h in 250 µL of complete RPMI medium and 2 ng/ml of hIL-2. After incubation, the cells were stained with PE-conjugated CD3 (Biolegend, catalog # 300308, clone HIT39) and PerCP-conjugated CD69 (Biolegend, catalog # 310926, clone FN50) antibodies. The percentage of CD69-expressing CD3+ T-cells was analyzed via flow cytometry as a measure of T-cell activation. CD107a degranulation assay To measure the degranulation of T-cells, control or BAFF CAR T-cells were co-incubated with HCL cell lines or patient samples at a 5:1 effector: target ratio in 250 µL of complete RPMI medium in the presence of 2 ng/mL of hIL-2. Cells were immediately stained with PE-Cy7-conjugated CD107a (Biolegend, catalog # 328617, clone H4A3). Monensin Golgistop protein transport inhibitor (BD Biosciences, catalog # 554724) was added after an hour of cell-plating. After another 5 h of co-incubation, cells were stained with PE-conjugated CD3 antibody (Biolegend, catalog #300407), and the percentage of CD3+ T-cells expressing CD107a was measured via flow cytometry. Multiplex cytokine release assay To measure the release of cytokines from T-cells, a Legendplex™ Multi-Analyte Flow Assay kit was used (Biolegend), and the manufacturer’s instructions were followed. The supernatant of cytotoxicity experiments was collected after initial centrifugation before PI staining. Twenty-five microliters of diluted samples were combined with 25 µL assay buffer and 25 µL of mixed fluorescent-encoded beads. Twenty-five microliters of biotinylated detection antibodies were then added, and samples were washed and analyzed on a flow cytometer. The assay was performed in a V-bottom, 96 well plate. In vivo tumor modeling In vivo experiments were approved by the CWRU IACUC and conducted according to IACUC protocol (2016–0307). Six to eight-week-old NSG mice were ordered from the CWRU Athymic Animal and Preclinical Therapeutics Core. They were housed in the CWRU Animal Resource Center (ARC) at the Wolstein Research Building or Small Animal Imaging Facility (SAIF) in University Hospitals in a pathogen-free environment. For the subcutaneous HCL model, NSG mice were inoculated subcutaneously in the right flank with 10 million Bonna-12 cells (50 µL) with Matrigel Matrix Basement Membrane support (50 µL) (Corning, catalog # CB-40234A). Tumors were treated intratumorally with PBS (50 µL) or 5 million BAFF CAR T-cells (50 µL) upon tumor formation of approximately 300 mm3. Tumors were retreated once tumor sizes reached approximately 500 mm3. Tumor volumes were measured biweekly via caliper measurements. The equation volume = (length × width2)/2 was used to calculate tumor volume. Mice were regularly observed for general illness and severity of tumors. They were euthanized when the maximal tumor burden was reached or presented with a clinical score over 60 per ARC veterinary services tumor scoring system. A second subcutaneous intratumoral model was performed. NSG mice were challenged with 10 million Bonna-12 cells (50 µL) subcutaneously in the right flank with 50 µL Matrigel Matrix Basement Membrane support. Tumors were treated intratumorally with 5 million untransduced control T-cells or BAFF CAR-T cells upon tumor formation of approximately 300 mm3 and retreated after 2 weeks. For the intravenous model, NSG mice were challenged with 7.5 million Hair-M cells via tail vein injection. Seven days after the inoculation, mice were treated with PBS control (n = 5) or 10 million BAFF CAR-T cells (n = 7). Mice were retreated 21 days after tumor inoculation. Mice were weighed and bled after treatments, and tumor cells and T-cells were measured in the peripheral blood by staining for APC: hCD19/PE: hCD45 (Biolegend, catalog numbers 115,312/982322) or PerCP: hCD3/PE: hCD45 (Biolegend, catalog numbers 300,325/982322). The Cal-Lyse™ Lysing Solution (catalog # GAS010) was used for blood processing following manufacturer’s instructions. Mice were monitored biweekly for signs of illness, including weight loss or hind limb paralysis. At day 30 post-inoculation, one mouse in the PBS group had hind limb paralysis, which was the endpoint of the study. All mice were euthanized, and tumor burden was measured in the bone marrow by gating on double positive hCD45 and hCD19 cells. Statistical analysis Data were compiled in Microsoft Excel (v2407), and statistical analyses were performed in GraphPad Prism (10.2.0). Statistical methods that were used to calculate significance are reported in figure legends. The statistical tests used throughout the study include unpaired two-tailed t-test, one-way analysis of variance (ANOVA) with Tukey correction for multiple hypothesis, two-way ANOVA with Holm-Šídák’s multiple comparisons correction, and survival analysis using the long-rank Mantel – Cox test. Error bars represent the standard deviation from the mean in all figures. The number of mice for in vivo experiments is included in appropriate figure legends. Results Hcl-v patient cells and cell lines express high levels of BAFF receptors A panel of HCL-v splenic patient samples and cell lines were stained with CD19, BCMA, TACI, and BAFF-Receptor antibodies, and surface expression of these receptors was measured by flow cytometry. Bonna-12, Hair-M and Mo-B are the HCL cell lines used and all the three cell lines express BAFF receptors BAFF-R, BCMA and TACI to varying degrees (Figure 1a, b). CD19 expression on these cells also shown for a comparison. Jeko-1 cells which are Mantle Cell Lymphoma cells, known to express BAFF receptors, were used as positive controls and Natural Killer (NK) cells served as negative controls as they lack expression of BAFF receptors (Figure 1a, b). Figure 1.HCL cell lines express all three BAFF receptors and are sensitive to BAFF CAR-T cells. HCL cells were stained with CD19 (FITC), BCMA (PE), TACI (PE/CY7), BAFF-R (APC) antibodies. The mantle cell lymphoma line JeKo-1 is included as a positive control and primary natural killer cells (NK) as an antigen negative control for receptor expression. Expression level of each receptor was measured via flow cytometry. Histograms were derived from live cell population from FSC/SSC gating (a). Median fluorescent intensity (MFI) of each receptor is derived from the respective histograms and the unstained control and stained samples are shown (b). Fluorescently labeled HCL cell lines were co-cultured with BAFF CAR-T cells at various effector: target ratios (2.5:1, 5:1, 10:1). After 16-24 h of incubation, cells were stained with propidium iodide and percentage of pi-positive cancer cells was quantified via flow cytometry (C shows gating strategy and D represents graphed percentage of PI+ (dead) cancer cells). ****p < 0.0001. Mean ± SD, n = 3 biologically independent co-cultures, two-way ANOVA with Holm- šídák’s multiple comparison test. HCL cell lines express all three BAFF receptors and are sensitive to BAFF CAR-T cells. HCL cells were stained with CD19 (FITC), BCMA (PE), TACI (PE/CY7), BAFF-R (APC) antibodies. The mantle cell lymphoma line JeKo-1 is included as a positive control and primary natural killer cells (NK) as an antigen negative control for receptor expression. Expression level of each receptor was measured via flow cytometry. Histograms were derived from live cell population from FSC/SSC gating (a). Median fluorescent intensity (MFI) of each receptor is derived from the respective histograms and the unstained control and stained samples are shown (b). Fluorescently labeled HCL cell lines were co-cultured with BAFF CAR-T cells at various effector: target ratios (2.5:1, 5:1, 10:1). After 16-24 h of incubation, cells were stained with propidium iodide and percentage of pi-positive cancer cells was quantified via flow cytometry (C shows gating strategy and D represents graphed percentage of PI+ (dead) cancer cells). ****p < 0.0001. Mean ± SD, n = 3 biologically independent co-cultures, two-way ANOVA with Holm- šídák’s multiple comparison test. Next, we tested the cytotoxic ability of the BAFF CAR-T cells using HCL cell lines. The cancer cells were fluorescently labeled and co-cultured with control or BAFF CAR-T cells at varying effector: target ratios for 16–24 h before PI staining and measurement of cancer cell death by flow cytometry. Relative to untransduced control T-cells, BAFF CAR-T cells demonstrated significantly enhanced cytotoxicity of cancer cells, with higher E:T ratios in a dose-dependent manner. At a 2.5:1 ratio, BAFF CAR-T cells induced more cell death of Hair-M (45%) than Bonna-12 (39%) cells. At a 5:1 ratio, Bonna-12 (56%) and HAIR-M (55%) displayed similarly enhanced cytotoxicity when co-cultured with BAFF CAR-T cells relative to untransduced controls. The cancer cell killing reached up to 75% in the 10:1 ratio of BAFF-CAR T cells co-incubated with Bonna-12 cells (Figure 1c, d). BAFF CAR-T cells show significant cytotoxicity against HCLv patient cells HCL-v is a rare disease, and confirming the expression of BAFF receptors on patient cells is warranted. Splenomegaly is a common symptom in HCL-v patients, and these malignant cells often home to spleen. Hence, we tested spleen cells from HCL-v patients for BAFF-R, BCMA and TACI expression. All the 10 patients tested showed expression of these BAFF receptors, at varying levels (Figure 2a, b). Jeko-1 cells were used as positive control and NK cells used as negative control. The cytotoxicity of the CAR T-cells against HCL-v patient splenic cells was significantly higher than that of the untransduced control T-cells at the same ratios. When BAFF CAR T-cells were co-cultured with multiple HCL splenic patient cells, the induced cancer cell death at a 10:1 E:T ratio ranged from 57–79% cell death, 46–62% at a 5:1 ratio, and 29–50% at a 2.5:1 ratio (Figure 2c, d). Figure 2.Hcl-v patient samples express all the BAFF receptors and are sensitive to BAFF CAR-T cells. hcl-c/v patient splenocytes were stained as in figure 1, with CD19 (FITC) BCMA (PE), TACI (PE/CY7), BAFF-R(APC) antibodies and overlayed flow histograms comparing the samples and controls are represented. Primary NK cells (NK) are used as an antigen negative control and the mantle cell lymphoma cell line JeKo-1, known to overexpress the receptors, is included as a positive control. The receptor expression is quantified from the histograms as MFI values and the unstained control and stained sample is shown (b). Multiple HCL patient-derived samples were labeled with eFluoro670 dye and co-incubated with BAFF CAR-T cells at various ratios (2.5:1, 5:1, 10:1, 20:1) for 16-24 h. The co-culture was then stained with propidium iodide. The flow gating strategy was to gate on APC positive cells (population P2) to distinguish the target cells and measure percent PI positivity in that population (shown as V2R) (c). The percent PI positive cancer cells were reported in bar graphs. ****p < 0.0001. Mean ± SD, n = 3 biologically independent co-cultures, two-way ANOVA with Holm- šídák’s multiple comparison test. (D). Hcl-v patient samples express all the BAFF receptors and are sensitive to BAFF CAR-T cells. hcl-c/v patient splenocytes were stained as in figure 1, with CD19 (FITC) BCMA (PE), TACI (PE/CY7), BAFF-R(APC) antibodies and overlayed flow histograms comparing the samples and controls are represented. Primary NK cells (NK) are used as an antigen negative control and the mantle cell lymphoma cell line JeKo-1, known to overexpress the receptors, is included as a positive control. The receptor expression is quantified from the histograms as MFI values and the unstained control and stained sample is shown (b). Multiple HCL patient-derived samples were labeled with eFluoro670 dye and co-incubated with BAFF CAR-T cells at various ratios (2.5:1, 5:1, 10:1, 20:1) for 16-24 h. The co-culture was then stained with propidium iodide. The flow gating strategy was to gate on APC positive cells (population P2) to distinguish the target cells and measure percent PI positivity in that population (shown as V2R) (c). The percent PI positive cancer cells were reported in bar graphs. ****p < 0.0001. Mean ± SD, n = 3 biologically independent co-cultures, two-way ANOVA with Holm- šídák’s multiple comparison test. (D). HCL-v cells are reported to express high levels of CD20, CD22 and CD11c. Some of them also reported to express CD103 or CD200 as well. Phenotypic analysis of cell surface markers on HCL-v patient cells confirmed high expression levels of CD20, CD22 and CD11c (Table 1). Nine of the ten patients analyzed were diagnosed with HCL-v, and one (PT 5) with classical HCL. All the patient cells shown in Table 1 expressed B-cell marker CD19, but CD103 was expressed only in five patients and CD200 expression in four patients (Table 1).Table 1.Summary of immunophenotyping data of hcl-v patients. HCL patient data was obtained from the Wilmont Cancer Institute of the University of Rochester. The data were collected from the clinical data system and anonymized. “PT” indicated anonymized patient number, which is conserved throughout the results (C). The numbering of patients (PT) is conserved through the remainder of the results. Immunophenotyping data were not available for patients 5 or 6.PTSexDiseaseCD11cCD19CD20FMC7CD22CD103CD2001MHCL-v✔✔✔✔✔✔✔2FHCL-v✔✔✔✔✔✔✔3MHCL-v✔✔✔✔✔✔ 4MHCL-v✔✔✔✔✔✔✔7MHCL-v✔✔✔✔✔ 8FHCL-v✔✔✔✔✔ 9MHCL-v✔✔✔✔✔✔✔10MHCL-v✔✔✔✔✔ Table 1.Summary of immunophenotyping data of hcl-v patients. HCL patient data was obtained from the Wilmont Cancer Institute of the University of Rochester. The data were collected from the clinical data system and anonymized. “PT” indicated anonymized patient number, which is conserved throughout the results (C). The numbering of patients (PT) is conserved through the remainder of the results. Immunophenotyping data were not available for patients 5 or 6.PTSexDiseaseCD11cCD19CD20FMC7CD22CD103CD2001MHCL-v✔✔✔✔✔✔✔2FHCL-v✔✔✔✔✔✔✔3MHCL-v✔✔✔✔✔✔ 4MHCL-v✔✔✔✔✔✔✔7MHCL-v✔✔✔✔✔ 8FHCL-v✔✔✔✔✔ 9MHCL-v✔✔✔✔✔✔✔10MHCL-v✔✔✔✔✔ Summary of immunophenotyping data of hcl-v patients. HCL patient data was obtained from the Wilmont Cancer Institute of the University of Rochester. The data were collected from the clinical data system and anonymized. “PT” indicated anonymized patient number, which is conserved throughout the results (C). The numbering of patients (PT) is conserved through the remainder of the results. Immunophenotyping data were not available for patients 5 or 6. BAFF CAR-T cells are activated after co-culture with hcl-v cell lines and patient samples CD107a expression was measured on control or BAFF CAR T -cells following co-incubation with HCL cell lines or patient samples, as a marker of T-cell degranulation. CD107a ligation is critical for cytotoxic immune cell activation and release of granzyme B and perforin. BAFF CAR T-cells or control T-cells were stained with CD107a antibody and co-cultured with HCL cells for 5 h, when CD107a+ CD3 cells were quantified. The percentage of CD107a-expressing BAFF CAR-T cells was significantly enhanced relative to untransduced control T-cells upon co-incubation with HCL cells Bonna-12 and Hair-M (Figure 3a) as well as splenic HCL patient samples (Figure 3a), confirming degranulation of BAFF CAR-T cells. We also measured CD69, a marker of T cell activation that is rapidly expressed by T-cells upon TCR/CD3 engagement, as an indication of BAFF CAR-T or control T-cell activation after co-culture with HCL cell lines or patient samples. In all three cell lines, the activation of BAFF CAR-T cells was significantly higher than that of control T-cells or CAR-T cells without co-incubation of cancer cells. Co-incubation with Bonna-12 cells induced activation of 58% of BAFF CAR-T cells, as measured by CD69 expression on CD3+ cells (Figure 4b). Fifty-three percent of BAFF CAR-T cells expressed CD69 when co-incubated with Hair-M, and 36% of BAFF CAR T-cells expressed CD69 when co-incubated with Mo-B (Figure 3b). When co-incubated with various patient samples, the percentage of BAFF CAR-T cells that were activated ranged from 46% to 59% (Figure 3b). Thus, activation and degranulation of BAFF CAR-T cells after co-incubation with HCL-v target cells was confirmed. Figure 3.BAFF CAR-T cells are activated and degranulated when co-cultured with HCL cells. BAFF CAR-T cells were co-cultured with hcl-c/v cell lines or patient samples at a 5:1 effector: target ratio, and PC7:CD107a was immediately added. Monensin Golgistop was added after an hour, and cells were stained with PE:CD3 after 7 total hours of co-incubation. The percent positive CD3+ cells expressing CD107a was quantified via flow cytometry analysis. ****p < 0.0001. Mean ± SD, n = 3 biologically independent experiments. ****p < 0.0001. Mean ± SD, two-way ANOVA with Holm- šídák’s multiple comparison test. (A). hcl-c/v cell lines or patient samples were co-cultured at a 5:1 effector: target ratio with BAFF CAR T-cells for 16 h, after which cells were stained with hCD3 (PE) and CD69 (PerCP5.5). Percentage of CD3+ cells expressing CD69 was quantified. ****p < 0.0001. Mean ± SD, n = 3 biologically independent experiments. ****p < 0.0001. Mean ± SD, two-way ANOVA with Holm- šídák’s multiple comparison test. (B). At least three T-cell donors were used for CAR-T generation. BAFF CAR-T cells are activated and degranulated when co-cultured with HCL cells. BAFF CAR-T cells were co-cultured with hcl-c/v cell lines or patient samples at a 5:1 effector: target ratio, and PC7:CD107a was immediately added. Monensin Golgistop was added after an hour, and cells were stained with PE:CD3 after 7 total hours of co-incubation. The percent positive CD3+ cells expressing CD107a was quantified via flow cytometry analysis. ****p < 0.0001. Mean ± SD, n = 3 biologically independent experiments. ****p < 0.0001. Mean ± SD, two-way ANOVA with Holm- šídák’s multiple comparison test. (A). hcl-c/v cell lines or patient samples were co-cultured at a 5:1 effector: target ratio with BAFF CAR T-cells for 16 h, after which cells were stained with hCD3 (PE) and CD69 (PerCP5.5). Percentage of CD3+ cells expressing CD69 was quantified. ****p < 0.0001. Mean ± SD, n = 3 biologically independent experiments. ****p < 0.0001. Mean ± SD, two-way ANOVA with Holm- šídák’s multiple comparison test. (B). At least three T-cell donors were used for CAR-T generation. Patient-derived BAFF CAR-T cells induce autologous cancer cell killing We isolated Peripheral Blood Mononuclear Cells (PBMCs) directly from a blood sample of an HCLv patient and autologous cytotoxicity assay was performed using same patient cells as target cells. We found that the CD19+ population in the HCLv patient-derived PBMCs expressed higher levels of the three BAFF receptors compared to PBMCs derived from a healthy donor (Figure 4a). The remaining PBMCs were used to successfully generate BAFF CAR-T cells according to our previously established protocol (Figure 4b). After both 20:1 and 10:1 E: T (Effector: Target) ratio co-culture, the patient-derived BAFF CAR-T cells demonstrated a significant reduction in the CD22+ live cell population (Figure 4c). Furthermore, when tested against the Hair-M cell line and a different spleen-derived patient sample (PT 6), the patient-derived CAR-T cells consistently demonstrated efficient cancer-cell killing (Figure 4c). Figure 4.Patient-derived BAFF CAR-T cells induce autologous cancer cell killing and BAFF CAR-T cells release proinflammatory cytokines when co-incubated with HCL cells. Total patient-derived PBMCs were stained with a panel of CD19 (FITC), PE(BCMA), TACI (PCY7), BAFF-R (APC) or CD22 (APC) flow antibodies and receptor expression was measured on flow cytometry and compared to a healthy donor control (a). The expression of BAFF receptors on cancer cells is analyzed by gating on the CD19+ population. T-cells were isolated from the remaining PBMCs, activated, and transduced with the pHR- BAFF CAR vector. The GFP reporter shows percent positive CAR-T cells following transduction and expansion (b). PBMCs from the same patient were co-incubated with control T cells or patient derived BAFF CAR-T cells for 16-24 h. Cells were stained with CD22 (APC) and live CD22+ cells were measured by FSC/SSC gating and live cell percentages are reported. ****p < 0.0001, *** = 0.002 for control T versus CAR-T in 10:1 experiment. Mean ± SD, one-way ANOVA with Tukey’s multiple comparison test. (c). Patient-derived BAFF CAR-T cells were co-incubated with fluorescently labeled hair-M cells (right) or cancer cells from a different patient (left), and live cancer cell percentage was measured by FSC/SSC gating via flow cytometry. ****p < 0.0001. Mean ± SD, one-way ANOVA with Tukey’s multiple comparison test (C). The supernatant from T-cells after co-culture with bonna-12 and hair-M cells for cytotoxicity experiments (figure 1D) was collected after 16 h of incubation. Various pro-inflammatory cytokines (d) and cytotoxic lytic enzymes (e) were measured with a multiplex cytokine release assay. ****p < 0.0001. Mean ± SD, two-way ANOVA with Holm- šídák’s multiple comparison test. Patient-derived BAFF CAR-T cells induce autologous cancer cell killing and BAFF CAR-T cells release proinflammatory cytokines when co-incubated with HCL cells. Total patient-derived PBMCs were stained with a panel of CD19 (FITC), PE(BCMA), TACI (PCY7), BAFF-R (APC) or CD22 (APC) flow antibodies and receptor expression was measured on flow cytometry and compared to a healthy donor control (a). The expression of BAFF receptors on cancer cells is analyzed by gating on the CD19+ population. T-cells were isolated from the remaining PBMCs, activated, and transduced with the pHR- BAFF CAR vector. The GFP reporter shows percent positive CAR-T cells following transduction and expansion (b). PBMCs from the same patient were co-incubated with control T cells or patient derived BAFF CAR-T cells for 16-24 h. Cells were stained with CD22 (APC) and live CD22+ cells were measured by FSC/SSC gating and live cell percentages are reported. ****p < 0.0001, *** = 0.002 for control T versus CAR-T in 10:1 experiment. Mean ± SD, one-way ANOVA with Tukey’s multiple comparison test. (c). Patient-derived BAFF CAR-T cells were co-incubated with fluorescently labeled hair-M cells (right) or cancer cells from a different patient (left), and live cancer cell percentage was measured by FSC/SSC gating via flow cytometry. ****p < 0.0001. Mean ± SD, one-way ANOVA with Tukey’s multiple comparison test (C). The supernatant from T-cells after co-culture with bonna-12 and hair-M cells for cytotoxicity experiments (figure 1D) was collected after 16 h of incubation. Various pro-inflammatory cytokines (d) and cytotoxic lytic enzymes (e) were measured with a multiplex cytokine release assay. ****p < 0.0001. Mean ± SD, two-way ANOVA with Holm- šídák’s multiple comparison test. BAFF CAR-T cells release proinflammatory cytokines and cytotoxic lytic enzymes when co-cultured with hcl-v cells We then used a multiplex, bead-based flow cytometry assay, to measure the release of pro-inflammatory cytokines and lytic enzymes from BAFF CAR-T cells when co-incubated with Bonna-12 or Hair-M cells. The assay was performed on supernatant from a co-culture of BAFF CAR- T cells and HCL cells for a cytotoxicity experiment (Figure 1d). After co-culture, BAFF CAR-T cells release a panel of proinflammatory cytokines, including TNF-α, IFN-γ, sFasL and the cytotoxic enzymes, Perforin, Granzyme A, Granzyme B, and Granulysin (Figure 4d and 4e, respectively). The release of these pro-inflammatory factors by BAFF CAR-T cells was significantly elevated when compared to basal cytokine release without the presence of cancer cells or to release from untransduced T-cells when co-cultured with HCL cells. BAFF CAR-T cells reduce in vivo tumor burden in xenograft mouse models The anti-cancer activity of the BAFF CAR T-cells was analyzed in two subcutaneous Bonna-12 models (Figure 5a, b). Mice were treated intra-tumorally at palpable tumor formation at approximately 300 mm3 and were re-treated at approximately 500 mm3. Treatment with BAFF CAR-T cells significantly decreased tumor volume and prolonged overall survival relative to PBS-treated mice (p < 0.0001, p = 0.0011, respectively) (Figure 5a). Tumor volume of the CAR T-treated mice continued to steadily decline until tumors were no longer palpable, while PBS-treated mice continued to increase until these mice were sacrificed per IACUC protocol (Figure 5a). Untransduced control T-cells were used as the control in a second subcutaneous model (Figure 5b). Mice were treated at tumor formation of approximately 300 mm3 and retreated after 2 weeks. Tumor burden in the control mice steadily increased until mice were sacrificed per IACUC guidelines, while tumors of CAR-T-treated mice steadily declined. Thus, BAFF CAR-T cells reduced tumor burden and prolonged overall survival relative to treatment with untransduced control T-cells (p < 0.0001, p = 0.0011). Figure 5.CAR-T cells reduce HCL tumor burden and prolong overall survival in vivo without toxicity. NSG mice were inoculated subcutaneously with 10 million bonna-12 cells (a). At formation of a palpable tumor of 300 mm3 at day 40, mice were treated intra-tumorally with PBS or 5 million BAFF CAR T-cells. Mice were retreated at day 47, when tumors volumes were approximately 500 mm.3 Mean ± SD, n = 5 mice per group. Two-way ANOVA with Holm-šídák correction for multiple comparisons was applied to tumor volume analysis over time, ****p-value <0.0001. Log rank (mantel-cox) test was applied for survival analysis, p = 0.0011. 10 million bonna-12 cells were injected subcutaneously in the right flank (B). Mice were treated intratumorally with 5 million untransduced control T-cells or BAFF CAR-T cells on days 21 and 39. 2-way ANOVA with Holm-šídák correction for multiple comparisons was applied to tumor volume analysis over time. ****p-value <0.0001, p = 0.049 (day 33), p = 0.0024 (day 36). Log rank (mantel-cox) test was applied for survival analysis, p = 0.0080,.NSG mice were inoculated with 7.5 million Hair-M cells via tail vein injection (b). Mice were treated with PBS (n = 5) or 10 million BAFF CAR-T cells (n = 7) on days 7 and 5 million on day 28. Weights were measured weekly. Percent change in body weight was calculated using the formula (final weight-initial weight)/initial weight. On day 30, one mouse in the PBS group was found with hind limb paralysis, and all mice were sacrificed. The bone marrow and peripheral blood were harvested, and tumor cells were measured by staining with hCD45 (PE) or hCD19 (APC). Unpaired two-tailed t-test was applied, p = 0.0005. CAR-T cells reduce HCL tumor burden and prolong overall survival in vivo without toxicity. NSG mice were inoculated subcutaneously with 10 million bonna-12 cells (a). At formation of a palpable tumor of 300 mm3 at day 40, mice were treated intra-tumorally with PBS or 5 million BAFF CAR T-cells. Mice were retreated at day 47, when tumors volumes were approximately 500 mm.3 Mean ± SD, n = 5 mice per group. Two-way ANOVA with Holm-šídák correction for multiple comparisons was applied to tumor volume analysis over time, ****p-value <0.0001. Log rank (mantel-cox) test was applied for survival analysis, p = 0.0011. 10 million bonna-12 cells were injected subcutaneously in the right flank (B). Mice were treated intratumorally with 5 million untransduced control T-cells or BAFF CAR-T cells on days 21 and 39. 2-way ANOVA with Holm-šídák correction for multiple comparisons was applied to tumor volume analysis over time. ****p-value <0.0001, p = 0.049 (day 33), p = 0.0024 (day 36). Log rank (mantel-cox) test was applied for survival analysis, p = 0.0080,. For the intravenous model, NSG mice were challenged with 7.5 million Hair-M cells via tail vein injection. Seven days and 14 days after inoculation, mice were treated with PBS (n = 5) or BAFF CAR-T cells (n = 7, 10 million cells). When mice in the PBS treated group showed hindlimb paralysis at day 30, all mice were sacrificed. PBS injected control group showed weight loss at day 28, while no significant weight loss seen in CAR-T cells injected mice (Figure 5b). The tumor burden in the bone marrow, as measured by human CD45 and human CD19 double positive staining, was significantly decreased in the CAR-T group relative to the control (p = 0.0005) (Figure 5c). Discussion HCL classical and HCL-variant diseases are rare indolent B-cell malignancies characterized by hairy cells and often show a characteristic immunophenotypic profile. The frontline treatment for HCL-v patients is chemoimmunotherapy. Ibrutinib, BTK inhibitor, has also shown efficacy in the treatment of HCL-v patients. Purine analogs alone or in combination with rituximab are the standard of care for HCL. However, patients become resistant to these drugs and often these treatments have side effects. Though cladribine induces complete response in majority of patients, it has strong side effects including immunosuppression and repeated infections. Patients who relapse are usually treated with another course of purine analog; however, response rates are often lower, and remissions shorter after relapse. Some of the emerging drugs for HCL and HCL-V include BTK inhibitors (BTKi), BRAF or MEK inhibitors and anti-CD22 immunotoxins. Here, we show HCL cell lines and HCL-v patient cells express all three BAFF receptors at varying degrees and can be effectively killed using BAFF CAR-T cells. Though the cell lines used in this study Bonna-12, Hair-M and Mo-B are considered HCL cell lines and are used in many studies, more phenotypic and functional characterization of these cell lines are further needed to confirm their identity. Bonna-12 and Hair-M cells do not have BRAF-V600E and hence their identity as HCL or HCL-v is yet to be confirmed. Patient cells used are from HCL-V patient’s spleen cells except one HCL-classic (HCL-c) patient cells. These patient cells express higher levels of BAFF-R and moderate levels of BCMA and TACI along with CD19. CD19-CAR T cell therapy has been extensively investigated in B cell malignancies and have demonstrated complete response rate (69–90%) in relapsed and refractory ALL in phase I trials. Despite promising efficacy, CD19-CAR-T therapy has problems of healthy B cell depletion (on target off tumor effect), CD19 negative tumor relapse, low activity of CAR-T cell, adverse cytokine release syndrome (CRS) and neurologic toxicity. CD19 is expressed on all B cells, but BAFF-R is expressed only on mature B cells, making it more specific antigen for targeting and narrowing down the side effects caused by off targeting. Furthermore, the development of CAR T-cell therapy for the treatment of classic or variant HCL has received little attention relative to other B-cell cancers. There is currently one Phase 1 clinical trial investigating anti-CD22 CAR T-cells currently underway [NCT04815356] and more such clinical trials are needed for treating this rare leukemia. We have reported earlier that BAFF CAR-T cells are able to kill B cell cancers including Non-Hodgkin Lymphoma and Multiple Myeloma even if they express any one of these three receptors.21 Even if antigen loss happens in these patients including HCL-v patients, they still will be sensitive to BAFF CAR-T therapy by binding to the other receptors and will avoid antigen escape. Here, we show that HCL cell lines and HCL-V patient cells express all three BAFF receptors and are sensitive to BAFF CAR-T killing. HCL xenograft mouse models are not well established. Here, we optimized two xenograft models for HCL/HCL-v by subcutaneous and intravenous injections of cancer cells and both models showed therapeutic effectiveness of BAFF CAR-T cells in vivo. We understand that a patient derived xenograft model is better to prove therapeutic efficacy, but it is very challenging to establish such a model for HCL as these patient cells fail to survive in mice after intravenous administration. We have previously ruled out the off-target effects of BAFF CAR-T in B cell cancer models,21 and now BAFF CAR-T has entered clinical trial for Non-Hodgkin Lymphoma (NCT05312801) and Multiple Myeloma (NCT05546723). These datapoint to a strong possibility of translating BAFF CAR-T therapy soon to clinic for these HCL-V patients with minimum side effects.